Organon welcomes Takeda's Ramona A. Sequeira to Board of Directors

• Organon has announcement the Ramona A. Sequeira’s appointment
• She will be taking the position of Board of Directors, serving in Talent Committee
• After the inclusion of Ramona, the organisation will have 12 directors in total.

A global healthcare company focused on women’s health, Organon (NYSE: OGN) has made an announcement regarding the appointment of Takeda Pharmaceutical Company Global Portfolio Division’s President Ramona A. Sequeira to the position of Board of Directors of the company which will be effective from July 1, 2025. After having her in the board, the size of the board of Organon will expand to a total of 12 directors.

In this new role, Ramona will serve on the Talent Committee of the board. In addition, she has been a part of Takeda for the last 10 years, serving in numerous roles.

Prior to joining her, she was associated with Lilly for two years as Vice President of Sales and Operations and with Eli Lilly and Company for over three years. She left this company at the role of VP, Neuroscience BU, Lilly USA.

With an extensive experience, she brings her expertise of handling multiple businesses across diverse markets, cultures, and healthcare systems.

Expressing excitement, Organon’s Board of Directors Chairman Carrie Cox said, “We are excited to strengthen our Board with the appointment of Ramona Sequeira. Her deep experience in commercial strategy will be a valuable asset to Organon as we continue to seek growth opportunities for our expansive and diverse portfolio.”

Headquartered in Jersey City, Organon caters in the Pharmaceutical Manufacturing industry with speciality in Pharma. It carries portfolio in therapies and products in women’s health with a company size of more than 10,000 and having 7,239 associated members.